F01 | Transmembrane potential
GO:0051881
Transmembrane potential
Transmembrane potential
| Compound | Dose | Time | Species | Model | Method | Action | Result | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|---|
| benzbromarone | 1 μmol/L | 1 hour | rat; Sprague–Dawley | hepatocytes | Measurement of mitochondrial membrane potential | decrease | Positive | p < 0.01 | 4 |
| benzbromarone | 4 μmol/L | 1 hour | rat; Sprague–Dawley | hepatocytes | Measurement of mitochondrial membrane potential | decrease | Positive | p < 0.01 | 4 |
| benzbromarone | 8 μmol/L | 1 hour | rat; Sprague–Dawley | hepatocytes | Measurement of mitochondrial membrane potential | decrease | Positive | p < 0.01 | 4 |
| benzbromarone | 20 μmol/L | 1 hour | rat; Sprague–Dawley | hepatocytes | Measurement of mitochondrial membrane potential | decrease | Positive | p < 0.01 | 4 |
| Amiodarone | 8 μmol/L | 1 hour | rat; Sprague–Dawley | hepatocytes | Measurement of mitochondrial membrane potential | decrease | Positive | p < 0.05 | 4 |
| Amiodarone | 20 μmol/L | 1 hour | rat; Sprague–Dawley | hepatocytes | Measurement of mitochondrial membrane potential | decrease | Positive | p < 0.01 | 4 |
| benzarone | 8 μmol/L | 1 hour | rat; Sprague–Dawley | hepatocytes | Measurement of mitochondrial membrane potential | decrease | Positive | p < 0.01 | 4 |
| benzarone | 20 μmol/L | 1 hour | rat; Sprague–Dawley | hepatocytes | Measurement of mitochondrial membrane potential | decrease | Positive | p < 0.01 | 4 |
| Amiodarone | 100 μmol/L | rat; Sprague–Dawley | hepatocytes | Measurement of oxygen uptake | affect | Positive | p < 0.01 | 4 | |
| benzarone | 50 μmol/L | rat; Sprague–Dawley | hepatocytes | Measurement of oxygen uptake | affect | Positive | p < 0.01 | 4 | |
| benzarone | 80 μmol/L | rat; Sprague–Dawley | hepatocytes | Measurement of oxygen uptake | affect | Positive | p < 0.01 | 4 | |
| benzarone | 100 μmol/L | rat; Sprague–Dawley | hepatocytes | Measurement of oxygen uptake | affect | Positive | p < 0.01 | 4 | |
| benzbromarone | 10 μmol/L | rat; Sprague–Dawley | hepatocytes | Measurement of oxygen uptake | affect | Positive | p < 0.01 | 4 | |
| benzbromarone | 20 μmol/L | rat; Sprague–Dawley | hepatocytes | Measurement of oxygen uptake | affect | Positive | p < 0.01 | 4 | |
| benzbromarone | 50 μmol/L | rat; Sprague–Dawley | hepatocytes | Measurement of oxygen uptake | affect | Positive | p < 0.01 | 4 | |
| benzbromarone | 80 μmol/L | rat; Sprague–Dawley | hepatocytes | Measurement of oxygen uptake | affect | Positive | p < 0.01 | 4 | |
| benzbromarone | 100 μmol/L | rat; Sprague–Dawley | hepatocytes | Measurement of oxygen uptake | affect | Positive | p < 0.01 | 4 | |
| Diclofenac | 12.5 μmol/L | 10 minutes | rat | liver mitochondria | Assessment of MPT | increase | Positive | not mentioned | 6 |
| Diclofenac | 25 μmol/L | 10 minutes | rat | liver mitochondria | Assessment of MPT | increase | Positive | not mentioned | 6 |
| Diclofenac | 50 μmol/L | 10 minutes | rat | liver mitochondria | Assessment of MPT | increase | Positive | not mentioned | 6 |
| Diclofenac | 100 μmol/L | 10 minutes | rat | liver mitochondria | Assessment of MPT | increase | Positive | not mentioned | 6 |
| Diclofenac | 50 μmol/L | 3 minutes | rat | liver mitochondria | Assessment of Mitochondrial Membrane Potential; incubated in the presence of Ca2+ | decrease | Positive | p < 0.01 | 6 |
| Cyclosporin A | 1 μmol/L | 3 minutes | rat | liver mitochondria | Assessment of Mitochondrial Membrane Potential; coincubated with diclofenac | decrease | Positive | p < 0.05 | 6 |
| DPPD | 1 μmol/L | 3 minutes | rat | liver mitochondria | Assessment of Mitochondrial Membrane Potential; coincubated with diclofenac | decrease | Positive | p < 0.05 | 6 |
| Diclofenac | 250 μmol/L | 24 hours | rat | hepatocytes | Assessment of Mitochondrial Membrane Potential | decrease | Positive | p < 0.01 | 6 |
| Diclofenac | 500 μmol/L | 24 hours | rat | hepatocytes | Assessment of Mitochondrial Membrane Potential | decrease | Positive | p < 0.01 | 6 |
| Metformin | 1 mM | 24 hours | human | hepatocytes | Measurement of mitochondrial membrane potential | decrease | Positive | 15 | |
| Metformin | 2 mM | 24 hours | human | hepatocytes | Measurement of mitochondrial membrane potential | decrease | Positive | 15 | |
| buformin | 75 μM | 24 hours | human | hepatocytes | Measurement of mitochondrial membrane potential | decrease | Positive | 15 | |
| Phenformin | 12.5 μM | 24 hours | human | hepatocytes | Measurement of mitochondrial membrane potential | decrease | Positive | 15 | |
| Perhexiline | 200 μM | mouse; Crl/CD-l(1CR)BR Swiss | liver mitochondria | Measurement of mitochondrial membrane potential | decrease | Positive | 193 | ||
| 2,4-dinitrophenol | increase | Positive | 24 | ||||||
| CCCP | increase | Positive | 27 | ||||||
| Salicylic acid | increase | Positive | 31 | ||||||
| benzbromarone | increase | Positive | 35 | ||||||
| Entacapone | increase | Positive | 35 | ||||||
| Menadione | increase | Positive | 35 | ||||||
| Nimesulide | increase | Positive | 35 | ||||||
| Primaquine | increase | Positive | 35 | ||||||
| Tolcapone | increase | Positive | 35 | ||||||
| Troglitazone | increase | Positive | 35 | ||||||
| 2,4-dinitrophenol | increase | Positive | 35 | ||||||
| CCCP | increase | Positive | 35 | ||||||
| FCCP | increase | Positive | 35 | ||||||
| Papaverine | increase | Positive | 35 | ||||||
| alpidem | increase | Positive | 36 | ||||||
| Diclofenac | increase | Positive | 39 | ||||||
| Diflunisal | increase | Positive | 40 | ||||||
| Hexachlorophene | increase | Positive | 42 | ||||||
| Ketoconazole | increase | Positive | 36 | ||||||
| lovastatin | increase | Positive | 36 | ||||||
| Nimesulide | increase | Positive | 36 | ||||||
| Nitrofurantoin | increase | Positive | 36 | ||||||
| Rosiglitazone | increase | Positive | 7 | ||||||
| sitaxsentan | increase | Positive | 44 | ||||||
| Sulindac | increase | Positive | 45 | ||||||
| Tamoxifen | increase | Positive | 46 | ||||||
| Troglitazone | increase | Positive | 7 | ||||||
| erlotinib | increase | Positive | 36 | ||||||
| imipramine | increase | Positive | 36 | ||||||
| Menadione | increase | Positive | 47 | ||||||
| Thioridazine | increase | Positive | 49 | ||||||
| pentamidine | increase | Positive | 51 | ||||||
| para-nonylphenol | rat | isolated liver mitochondria | measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay | increase | Positive | 53 | |||
| ezlopitant | rat | isolated liver mitochondria | measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay | increase | Positive | 53 | |||
| procarbazine | rat | isolated liver mitochondria | measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay | increase | Positive | 53 | |||
| rifabutin | rat | isolated liver mitochondria | measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay | increase | Positive | 53 | |||
| ritolukast | rat | isolated liver mitochondria | measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay | increase | Positive | 53 | |||
| Trifluoperazine | rat | isolated liver mitochondria | measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay | increase | Positive | 53 | |||
| crizotinib | rat | isolated liver mitochondria | measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay | increase | Positive | 53 | |||
| tenidap | rat | isolated liver mitochondria | measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay | increase | Positive | 53 | |||
| benztropine mesylate | rat | isolated liver mitochondria | measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay | increase | Positive | 53 | |||
| clemastine | rat | isolated liver mitochondria | measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay | increase | Positive | 53 | |||
| darifenacin | rat | isolated liver mitochondria | measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay | increase | Positive | 53 | |||
| protriptyline | rat | isolated liver mitochondria | measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay | increase | Positive | 53 | |||
| tolterodine | rat | isolated liver mitochondria | measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay | increase | Positive | 53 | |||
| chenodeoxycholic acid | rat | isolated liver mitochondria | increase | Positive | 55 | ||||
| Etodolac | isolated mitochondria | increase | Positive | 56 | |||||
| Bupivacaine | decrease | Positive | 61 | ||||||
| Bupivacaine | decrease | Positive | 61 | ||||||
| aristolochic acid | isolated kidney mitochondria | increase | Positive | 64 | |||||
| Indomethacin | rat | isolated liver mitochondria | increase | Positive | 65 | ||||
| ochratoxin a | rat | isolated liver mitochondria | increase | Positive | 66 | ||||
| Paraquat | increase | Positive | 67 | ||||||
| Paraquat | increase | Positive | 67 | ||||||
| Mersalyl | 130 μM | bovine | heart MF0, proton conductivity | affect | Positive | 70% inhibition | 170 | ||
| (1,1,3,3-tetramethylbutyl)phenol | 2.85±0.86 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| (1'-ethyl-6,7-dihydro-5h-spiro[furo[2,3-f]indole-3,4'-piperidin]-5-yl)[2'-methyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-yl]methanone hydrochloride | 6.09±2.54 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| (2-ethyl-4-{[(4-{[4-(4-methoxyphenyl)piperazin-1-yl]methyl}-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]sulfanyl}phenoxy)acetic acid | 25.29±5.81 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| (2-nitro-1-propenyl)benzene | 38.57±15.32 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| (5-chloro-2-hydroxyphenyl)phenylmethanone | 29.09±3.36 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| (5s,8s)-5-(3,4-dichlorophenyl)-8-(methylamino)-5,6,7,8-tetrahydronaphthalene-2-sulfonamide | 8.31±1.43 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| (9z)-octadec-9-enamide | 41.61±7.16 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| (acryloyloxy)(tributyl)stannane | 0.19±0.11 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| (n-6)-methyladenine | 5.98±5.84 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-(2,3,8,8-tetramethyl-1,2,3,4,5,6,7,8-octahydronaphthalen-2-yl)ethanone | 27.31±20.44 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-(3,5,5,6,8,8-hexamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethanone | 30.64±18.87 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,1,1-trichloropropanone | 1.22±0.56 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,1,2-trimethyl-1h-benzo[e]indole | 23.42±4.03 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,1':3',1''-terphenyl | 47.88±14.29 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,2,5,6,9,10-hexabromocyclododecane | 6.93±1.95 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,2-benzisothiazolin-3-one | 38.57±13.65 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,2-phenylenediamine | 3.90±3.61 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,2-phenylenediamine dihydrochloride | 0.44±0.20 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,3,5-tris(4-tert-butyl-3-hydroxy-2,6-dimethylbenzyl)-1,3,5-triazinane-2,4,6-trione | 12.20±2.84 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,3-didecyl-2-methylimidazolium chloride | 3.86±4.19 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,3-diiminobenz(f)isoindoline | 11.08±7.81 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,3-diphenyl-1,3-propanedione | 11.68±1.35 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,4-benzenediamine | 3.28±0.42 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,4-diaminoanthraquinone | 0.03±0.01 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,4-dihydroxyanthracene-9,10-dione | 5.24±3.43 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,4-naphthalenediamine | 0.20±0.08 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,5-naphthalenediamine | 17.00±19.61 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,8-dihydroxy-4,5-dinitroanthraquinone | 0.07±0.04 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 10-chloro-9-anthraldehyde | 13.87±7.82 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Mito-4509 | 37.81±13.89 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 17alpha-ethinylestradiol | 19.12±5.99 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-amino-2,4-dibromoanthraquinone | 2.78±3.75 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-amino-2-methylanthraquinone | 0.64±0.08 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-benzyl-1-{[3-(4-chlorophenyl)-5-methyl-1-benzofuran-2-yl]methyl}-3-(2,4,6-trifluorophenyl)urea | 21.01±2.43 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-decyl-3-methylimidazolium tetrafluoroborate | 3.87±16.67 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-decyl-3-methylimidazolium trifluoromethanesulfonate | 1.67±2.71 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-dodecyl-3-methylimidazolium hexafluorophosphate | 3.71±8.52 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-fluoro-2,4-dinitrobenzene | 3.71±0.60 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1h,3h-naphtho(1,8-cd)pyran-1,3-dione | 3.89±1.12 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1h-benzo[de]isoquinoline-1,3(2h)-dione | 8.31±3.47 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1h-indole-2-carboxamide, n-[(3r)-1-(2-fluorophenyl)-3,4,6,7-tetrahydro-4-oxopyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- | 8.41±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-hydroxypyrene | 4.67±1.95 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-isocyanato-3-(trifluoromethyl)benzene | 3.28±1.13 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-methyl-3-octylimidazolium hexafluorophosphate | 8.23±5.05 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-methyl-3-octylimidazolium tetrafluoroborate | 5.66±5.82 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-methyl-3-octylimidazolium trifluoromethanesulfonate | 8.38±4.29 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-methylpyrene | 43.23±4.99 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-naphthol | 31.04±5.96 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-nitronaphthalene | 59.74±7.06 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-nitropyrene | 2.01±2.06 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Edaravone | 31.75±4.28 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-trans-delta-9-tetrahydrocannabinol | 4.99±1.66 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-(4-hydroxybenzyl)phenol | 27.47±1.92 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-(butan-2-yl)phenol | 49.48±9.45 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-(thiocyanomethylthio)benzothiazole | 33.08±4.58 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2',4,4',5-pentabromodiphenyl ether | 8.00±3.19 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2',6,6'-tetrachlorobisphenol a | 4.86±3.13 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2'4,4'-tetrabromodiphenyl ether | 22.56±5.18 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane | 8.78±1.43 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2-bis[(benzoyloxy)methyl]dibenzoate propanediol | 4.32±8.63 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2'-dichlorobiphenyl | 31.09±12.28 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2'-dihydroxy-4,4'-dimethoxybenzophenone | 7.75±1.80 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2'-dihydroxy-4-methoxybenzophenone | 9.89±1.04 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2'-methylenebis(4-methyl-6-tert-butylphenol) | 1.35±0.26 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2'-methylenebis(ethyl-6-tert-butylphenol) | 1.22±0.73 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,3',4,4'-tetrahydroxybenzophenone | 7.39±7.14 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,3,4,5-tetrachlorophenol | 4.93±2.04 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,3,4-trichlorophenol | 5.23±1.52 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,3,5,6-tetrachlorophenol | 6.42±2.38 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,3,5-trichlorophenol | 5.80±1.05 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4,5-trichlorophenol sodium salt | 5.05±2.09 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4,6-trinitro-1,3-dimethyl-5-tert-butylbenzene | 20.09±6.09 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4-bis(1-methyl-1-phenylethyl)phenol | 3.49±1.51 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4-diaminoanisole sulfate | 2.51±1.16 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4-diaminophenol dihydrochloride | 3.77±1.06 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4-dichloro-3,5-dimethylphenol | 5.88±4.85 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4-diisopropylphenol | 17.23±1.99 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4-di-tert-butylphenol | 3.50±0.73 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,5-bis(2-methylbutan-2-yl)benzene-1,4-diol | 6.86±3.17 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,5-di-tert-butylbenzene-1,4-diol | 7.41±1.27 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,6-bis-(1,1-dimethylethyl)-2,5-cyclohexadiene-1,4-dione | 18.60±12.40 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,6-di(butan-2-yl)phenol | 13.69±3.19 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,6-diaminopyridine | 31.28±10.35 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,6-di-tert-butyl-4-nitrophenol | 0.17±0.05 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,6-toluenediamine | 15.70±10.03 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 24r,25-dihydroxyvitamin d3 | 13.02±2.17 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-Acetylaminofluorene | 36.27±10.50 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-amino-4-(p-nitrophenyl)thiazole | 3.90±1.78 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-amino-4,6-dinitrophenol | 4.18±2.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-amino-4-chloro-5-nitrophenol | 21.51±2.48 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-amino-4-chlorobenzothiazole | 29.57±5.09 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-amino-5-nitrophenol | 27.40±14.08 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-amino-6-nitrobenzothiazole | 12.69±10.45 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-aminoanthracene | 4.71±1.92 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-aminoanthraquinone | 0.51±0.29 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-chloro-4-phenylphenol | 15.36±7.86 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-dodecylisoquinolinium tosylate | 3.53±0.50 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-hydrazino-4-(4-aminophenyl) thiazole | 0.06±0.02 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-hydrazino-4-(4-nitrophenyl)thiazole | 1.60±0.29 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-hydrazino-4-phenylthiazole | 2.32±0.79 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-hydroxyanthraquinone | 3.31±1.38 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-isovaleryl-1,3-indanedione | 5.24±0.90 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-methyl-1-nitroanthraquinone | 1.34±0.15 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-methylanthraquinone | 6.33±1.15 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-naphthalenesulfonic acid, 7-amino-4-hydroxy- | 27.33±3.73 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-naphthalenol | 50.10±16.03 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-nitro-1,4-phenylenediamine | 7.07±6.53 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-nitrofluorene | 12.19±0.86 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-pentylfuran | 42.19±2.81 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-phenylphenol | 17.90±1.41 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-propenal,3,3-diphenyl- | 41.19±19.34 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-tert-butyl-4-ethylphenol | 11.30±2.60 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-tert-butyl-4-methoxyphenol | 25.29±1.71 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-tert-butyl-5-methylphenol | 23.48±2.85 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-(5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexanol | 31.84±17.54 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,3',4,4'-tetraaminobiphenyl tetrahydrochloride | 0.34±0.26 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,3',5,5'-tetraiodothyroacetic acid | 45.79±2.99 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,3'-diaminobenzidine | 13.69±14.86 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,3'-dimethylbisphenol a | 8.88±3.37 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,3φ,5,5φ-tetrabromobisphenol a | 13.23±12.24 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,4,5-trichlorophenol | 3.80±1.74 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,4-dichlorophenol | 9.18±2.63 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,5-dichlorophenol | 9.79±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,5-dichlorosalicyl-3,4-dichloroanilide | 0.22±0.09 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-acetylphenanthrene | 36.89±13.68 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-amino-9-ethylcarbazole hydrochloride | 35.36±24.49 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-hydroxybenzophenone | 27.72±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-hydroxy-n-(3-nitrophenyl)naphthalene-2-carboxamide | 0.24±0.09 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-hydroxy-n-phenylaniline | 28.48±6.04 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-methylbenzene-1,2-diamine | 21.74±3.65 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-methylcholanthrene | 17.26±13.23 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-methyl-n-phenylaniline | 48.56±5.61 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-(1,1,3,3-tetramethylbutyl)phenol | 4.25±0.92 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-(2-methylbutan-2-yl)phenol | 22.71±3.07 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-(3-phenylpropyl)pyridine | 16.58±6.74 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-(benzyloxyl)phenol | 18.46±1.51 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-(butan-2-yl)phenol | 31.98±3.64 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4,4-trifluoro-1-phenyl-1,3-butanedione | 20.37±6.17 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-diaminoazobenzene | 10.45±3.59 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-diaminobenzanilide | 3.72±2.85 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-dichlorodiphenyl sulfone | 21.27±6.06 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-dinitrodiphenylurea | 0.46±0.06 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-methylenebis(2-chloroaniline) | 49.14±17.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-sulfonylbis[2-(prop-2-en-1-yl)phenol] | 44.97±17.92 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-thiobis(6-tert-butyl-m-cresol) | 1.86±1.18 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-thiodiphenol | 21.08±2.70 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,6-dichloro-1,3-benzenediol | 9.55±2.74 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,6-di-tert-butyl-m-cresol | 2.25±1.49 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-amino-2,6-dichlorophenol | 17.23±13.38 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-amino-2-nitrophenol | 15.42±10.56 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-amino-4φ-hydroxy-3-methyldiphenylamine | 7.66±0.88 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-benzylphenol | 15.94±3.38 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-chloro-1,2-diaminobenzene | 2.38±1.60 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-chloro-2-cyclopentylphenol | 5.66±1.93 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-chloro-3,5-dimethylphenol | 21.00±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-chlorophenyl isocyanate | 0.27±0.11 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-cumylphenol | 3.70±0.82 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4'-demethylepipodophyllotoxin | 2.66±3.92 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-dodecylphenol | 3.18±0.58 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-hexyl-4'-cyanobiphenyl | 42.53±15.42 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-hydroxybenzophenone | 41.31±18.12 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-methyl-2,6-dinitrophenol | 26.55±4.57 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-nitroanthranilic acid | 38.57±17.22 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-nitro-n-phenylaniline | 7.43±6.54 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-nitrosophenol | 4.71±2.31 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-octyloxybenzoic acid | 39.63±31.34 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-octylphenol | 8.77±2.96 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-phenoxyphenol | 27.97±10.62 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-styrylpyridine | 11.22±5.54 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-tert-butylcatechol | 34.27±14.96 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-tert-butylphenyl salicylate | 28.37±3.64 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 5,7-dichloro-8-hydroxy-2-methylquinoline | 11.01±2.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 5alpha-dihydrotestosterone | 13.30±6.16 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 5hpp-33 | 2.09±0.87 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Busulfan | 14.43±5.99 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 5-nitroacenaphthene | 34.38±20.44 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 6-hydroxy-2-naphthyl disulfide | 33.74±3.64 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 6-nitrobenzimidazole | 36.41±10.82 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 6-nitroquinoline | 30.73±11.46 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 9,10-dihydrobenzo[a]pyren-7(8h)-one | 9.81±2.08 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 9-aminoacridine, monohydrochloride, monohydrate | 13.80±1.75 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 9-anthracenemethanol | 34.48±11.46 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 9-cyanoanthracene | 6.85±18.05 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 9-nitroanthracene | 21.44±12.82 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 9-phenanthrol | 1.22±0.56 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| acenocoumarol | 8.36±1.07 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| acetaldehyde | 18.02±6.38 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| aclarubicin hydrochloride | 3.15±2.82 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| acriflavine hydrochloride | 0.94±0.44 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Albendazole | 9.35±1.83 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| aldrin | 31.20±7.21 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| alizarin | 11.01±1.41 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| allylestrenol | 12.83±3.68 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| aloe-emodin | 1.79±1.54 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| alpha-1,2,3,4,5,6-hexachlorocyclohexane | 49.00±6.35 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| alpha-amylcinnamyl alcohol | 38.11±17.40 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ambazone | 5.60±3.23 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ami-193 | 5.82±3.05 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| aminoquinuride dihydrochloride | 25.01±4.09 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| amorolfine | 21.61±3.47 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| amsacrine hydrochloride | 10.34±2.45 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| amylmetacresol | 11.17±0.65 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| anthrone | 21.84±9.90 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| apigenin | 1.61±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| aranidipine | 12.83±3.68 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| aroclor 1260 | 21.47±2.75 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| arotinolol hydrochloride | 17.04±3.45 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| axitinib | 3.76±2.80 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| barban | 22.54±4.10 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bardoxolone methyl | 5.11±1.27 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| barium bis(2-ethylhexanoate) | 15.36±10.31 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| barium chloride | 16.58±8.50 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| basic blue 7 | 0.02±0.03 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bazedoxifene | 11.01±0.75 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| beclazone | 23.71±2.74 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benzbromarone | 7.22±1.24 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benzidine | 24.34±4.50 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benziodarone | 2.98±0.63 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benzobarbital | 24.07±5.12 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benzoic acid, 2-[(4-chloro-3-methylphenyl)amino]- | 12.83±0.84 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benzyldimethyltetradecylammonium chloride dihydrate | 16.40±4.28 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benzyldodecyldimethylammonium bromide | 11.44±4.34 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benzylhydrazine dihydrochloride | 27.81±3.21 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| berberine chloride | 2.03±1.29 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| betamethasone dipropionate | 25.60±1.67 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bexarotene | 16.49±3.95 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bis(tributyltin)oxide | 0.09±0.02 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bisacodyl | 14.82±3.63 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Bisphenol A | 13.97±6.29 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bisphenol a glycidyl methacrylate | 12.20±11.86 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bisphenol af | 5.44±1.42 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bisphenol b | 10.66±2.48 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bisphenol e | 27.64±1.80 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bisphenol z | 22.19±5.51 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bithionol | 0.66±0.52 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bosutinib | 0.75±0.48 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bromadiolone | 16.67±1.13 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bromociclen | 33.18±3.47 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bromocriptine | 11.44±1.58 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bromocriptine mesylate | 11.19±2.78 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bromofenoxim | 1.08±0.25 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bromofos | 7.70±1.63 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bromoxynil octanoate | 15.29±5.08 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| broquinaldol | 26.60±4.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bryostatin 1 | 0.01±0.01 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| buclizine dihydrochloride | 32.23±2.10 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| butylparaben | 19.00±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| c.i. 1040 | 8.10±1.39 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| c.i. basic orange 2 | 7.53±5.61 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| c.i. basic red 9 monohydrochloride | 0.08±0.02 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| c.i. basic violet 14 | 0.18±0.16 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| c.i. disperse blue 27 | 2.34±0.87 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| c.i. solvent yellow 14 | 5.84±2.06 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| calcifediol | 5.82±0.47 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| calcipotriene | 25.98±3.89 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| calcitriol | 14.06±4.15 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| candesartan cilexetil | 15.94±4.62 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cannabinol | 1.68±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cantharidin | 0.15±0.08 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| CCCP | 0.15±0.04 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| carminomycin | 1.25±0.73 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chlorfenapyr | 0.07±0.04 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chlorfenethol | 26.28±7.53 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chlorfenson | 38.83±25.41 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chlorfluazuron | 8.93±4.57 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chlorophacinone | 0.64±0.25 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chloropropylate | 26.28±3.64 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chloroxine | 10.59±1.22 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chromomycin | 12.35±0.84 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chrysarobin | 22.82±3.93 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chrysin | 5.05±2.76 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ciclesonide | 7.91±1.38 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Ciglitazone | 8.22±1.60 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cilnidipine | 12.53±1.78 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cinalukast | 28.81±1.17 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| clobetasol | 14.40±3.67 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| clobetasol propionate | 24.64±1.67 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cloflucarban | 0.60±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| clofoctol | 1.64±0.13 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| clonixin | 19.86±6.75 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cloxyquin | 16.79±5.94 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| coumatetralyl | 13.69±4.84 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cresyl diphenyl phosphate | 2.38±2.32 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| curcumin | 1.31±1.03 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cybutryne | 20.87±13.91 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cyclododecanol | 48.78±3.84 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cyhalothrin | 33.62±5.79 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| d&c yellow 11 | 0.38±0.13 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| danthron | 4.66±1.19 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dantrolene sodium | 4.35±1.73 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| darbufelone mesylate | 11.74±2.02 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| deltamethrin | 45.88±17.92 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| deslanoside | 1.84±0.23 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| desogestrel | 22.29±2.11 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| devazepide | 12.53±5.62 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dexamethasone valerate | 12.06±4.39 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diacerein | 20.64±8.26 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dianiline | 18.40±5.73 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dichlofluanid | 5.24±1.99 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dichlorodiphenylsilane | 12.96±9.66 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diclazuril | 11.17±2.79 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dicofol | 9.69±3.51 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| N,N'-dicyclohexylcarbodiimide | 0.30±0.20 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dienestrol | 10.93±1.88 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Diethylstilbestrol | 9.76±6.25 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diethylstilbestrol dipropionate | 10.46±2.66 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diflorasone diacetate | 28.73±1.87 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| digitoxin | 0.16±0.05 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| digoxin | 0.52±0.09 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dihydrotachysterol | 32.71±1.32 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dinex | 0.28±0.34 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diniconazole | 12.18±3.53 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dinobuton | 4.33±1.24 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dinocap | 0.34±0.30 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dinoterb | 0.48±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diphenan | 22.29±4.67 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diphenoxylate hydrochloride | 20.65±1.19 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diphenylcyclopropenone | 25.60±1.67 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diphenylurea | 1.60±0.74 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| disperse red 82 | 8.00±1.45 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dithiazanine chloride | 0.27±0.82 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dithiazanine iodide | 0.10±0.15 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| docetaxel | 14.96±29.77 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dodecyl gallate | 4.75±1.81 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dodecylparaben | 4.19±1.07 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dodecylphenol | 3.10±1.22 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| doramapimod;bibr-796? | 21.13±5.52 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| doramectin | 11.88±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ebselen | 23.16±0.93 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| emodin | 1.33±0.78 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| endosulfan sulfate | 15.96±2.05 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| endrin | 23.52±7.96 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| enterolactone | 9.99±5.02 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| eprinomectin (b1a, b1b mixture) | 4.22±0.90 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| equilin | 24.34±4.60 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ergotamine d-tartrate | 7.55±1.06 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| estradiol acetate | 9.08±0.59 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ethacridine lactate hydrate | 3.22±0.55 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ethalfluralin | 43.28±17.60 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ethanol, 2,2'-((1-methylethylidene)bis((2,6-dibromo-4,1-phenylene)oxy))bis- | 6.21±0.42 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ethoxazene | 2.70±1.13 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ethyl linolenate | 49.65±36.02 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ethynodiol diacetate | 15.40±0.84 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| etocarlide | 17.04±6.52 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| everolimus | 19.86±2.83 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| exalamide | 9.81±3.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ezetimibe | 25.60±3.54 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| famoxadone | 4.19±1.07 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fenamidone | 43.28±17.10 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fenarimol | 42.59±21.91 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fenchlorphos | 13.62±2.52 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fendiline hydrochloride | 10.34±1.55 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fenhexamid | 8.31±1.15 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fenobam | 25.85±1.87 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fenretinide | 3.40±0.76 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fentiazac | 27.43±2.92 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fenticlor | 2.15±0.36 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fenvalerate | 32.06±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| flopropione | 18.83±6.83 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fluazuron | 3.96±2.31 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| flubendiamide | 18.72±2.59 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| flucythrinate | 35.72±20.02 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Flufenamic Acid | 36.64±1.87 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| flunixin meglumine | 9.02±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fluorodifen | 27.31±25.06 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fluorosalan | 0.24±0.09 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fluoxastrobin | 45.79±15.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fluticasone propionate | 9.02±1.71 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fluvastatin | 27.64±1.87 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| folpet | 8.25±0.54 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| forchlorfenuron | 0.45±0.13 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| formononetin | 13.17±4.88 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fulvestrant | 5.86±0.82 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| geliomycin | 0.52±0.04 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| genistein | 6.34±0.77 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| gentian violet | 0.08±0.04 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| glycyrrhetinic acid | 40.10±9.34 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| gramicidin | 0.51±0.42 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| halobetasol propionate | 15.18±5.52 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| heptachlor | 39.40±17.92 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Hexachlorophene | 0.70±0.46 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| hydroxystilbamidine bis(methanesulfonate) | 2.81±0.90 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| idarubicin hydrochloride | 6.83±1.46 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| idazoxan | 20.64±7.46 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| indole-3-pyruvic acid | 28.92±16.69 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| indoxacarb | 12.73±3.65 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| iodophthalein | 5.31±1.76 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| iodophthalein sodium | 10.75±3.91 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| isobutylparaben | 14.21±1.82 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| isodrin | 43.28±15.32 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| isoxaben | 26.32±5.75 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| isoxicam | 5.18±2.90 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| israpafant | 21.96±1.49 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| kaempferol | 2.56±3.04 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| kepone | 0.93±0.65 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Ketoconazole | 10.81±3.25 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lambda-cyhalothrin | 24.35±1.59 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lanatoside a | 0.43±0.04 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lanatoside b | 1.10±0.20 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lanatoside c | 0.78±0.14 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lapachol | 26.12±1.70 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lasalocid sodium | 1.14±0.07 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lercanidipine hydrochloride | 6.53±0.53 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lestaurtinib | 4.80±0.97 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lopinavir | 32.71±1.32 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lornoxicam | 9.44±1.09 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lufenuron | 7.65±0.70 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lynestrenol | 16.63±2.15 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lysergide | 9.03±1.87 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| malachite green oxalate | 2.10±1.87 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| malotilate | 14.96±1.99 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| manidipine | 12.15±6.82 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Mebendazole | 2.45±0.34 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Meloxicam | 14.47±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| mepartricin | 23.16±6.59 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| mepronil | 40.86±19.18 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| mesotrione | 17.97±11.96 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| metanixin | 25.98±2.11 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methfuroxam | 25.78±1.71 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methisazone | 5.82±1.38 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Methoxychlor | 26.28±8.69 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methyl 2,4-dihydroxy-3,6-dimethylbenzoate | 15.96±6.62 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methyl triclosan | 25.53±1.67 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methyl violet | 0.07±0.03 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methyldigoxin | 0.73±0.09 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Methylene Blue | 2.88±1.33 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methylene blue trihydrate | 1.31±0.79 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methylsilanetriyl triacetate | 29.07±16.38 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methyltrioctylammonium trifluoromethanesulfonate | 2.16±0.72 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| metochalcone | 18.18±10.11 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| mgk-264 | 15.36±10.52 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| mifepristone | 16.13±32.54 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| miripirium chloride | 16.40±4.01 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| mk-2206 | 17.78±7.38 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| mometasone furoate | 11.80±0.80 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| montelukast sodium | 32.71±1.32 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| n,n-diethylbenzene-1,4-diamine | 49.89±3.51 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| n,n-dimethyl-p-phenylenediamine | 9.10±0.59 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| n,nφ-diethylcarbanilide | 21.69±38.23 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| n-benzyl-6-ethoxy-4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxamide | 14.78±9.66 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| n-cyclohexyl-4-methyl benzenesulfonamide | 36.15±20.97 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| nelfinavir mesylate | 11.88±6.92 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Niclosamide | 0.03±0.01 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| niflumic acid | 13.02±2.17 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| nifuroxazide | 1.57±0.30 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Nimesulide | 3.87±0.23 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ninhydrin | 32.00±9.69 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Nitazoxanide | 1.04±0.96 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Nitrofurantoin | 26.31±6.35 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| nitrovin | 3.27±0.57 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| nitroxoline | 9.22±2.41 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| n-methyl-n,n-dioctyloctan-1-aminium chloride | 2.73±0.32 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| nocodazole | 3.53±1.63 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| nonylparaben | 4.43±0.30 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| norelgestromin | 13.53±6.64 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| noristerat | 9.81±1.78 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| n-phenyl-1,4-benzenediamine hydrochloride | 5.82±6.96 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| o,p'-ddd | 19.83±0.94 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| o,p'-ddt | 23.98±12.11 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| olvanil | 13.53±1.90 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| osalmid | 6.68±0.77 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ouabain | 0.18±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| oxyphenisatin acetate | 5.49±4.60 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| p,p'-ddd | 15.19±8.82 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| p,p'-dde | 25.60±1.71 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| p,p'-ddt | 24.26±2.74 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| palmatine chloride hydrate | 22.74±5.23 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| paricalcitol | 8.91±1.56 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| p-benzoquinone dioxime | 43.30±14.86 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| penfluridol | 33.49±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2',4,4',5-pentabromodiphenyl ether | 15.46±7.01 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| pentabromophenol | 3.46±0.99 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Pentachlorophenol | 3.09±0.60 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| pentylparaben | 8.74±1.65 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| perfluorooctanesulfonamide | 2.43±0.81 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| phenazopyridine hydrochloride | 15.72±3.45 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| phenmedipham | 4.41±2.02 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| phenol, 4,4'-butylidenebis[2-(1,1-dimethylethyl)-5-methyl- | 5.51±1.58 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| phenol, 4-methyl-, reaction products with dicyclopentadiene and isobutylene | 15.55±8.56 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| phenolphthalein | 42.78±2.74 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| phenoxybenzamine hydrochloride | 48.80±9.17 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| phenyl isothiocyanate | 43.01±14.76 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| phloretin | 4.26±1.22 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| picoxystrobin | 9.31±2.67 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| picropodophyllin | 0.14±0.02 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| pinacyanol | 0.01±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| pirarubicin | 0.60±0.46 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| pirenoxine sodium | 21.13±17.82 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Piroxicam | 8.21±1.71 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| polyethylene glycol (9z)-9-octadecenyl ether | 7.50±18.45 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| polyoxyethylene(10)nonylphenyl ether | 10.20±6.92 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| p-phenylazophenol | 4.06±1.23 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| prodiamine | 4.84±0.56 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| profenofos | 2.54±1.84 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| proflavin hemisulfate | 3.22±0.82 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| proflavin hydrochloride | 1.66±0.63 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| profluralin | 21.69±8.04 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| propan-2-yl (2r,4s)-4-{acetyl[3,5-bis(trifluoromethyl)benzyl]amino}-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2h)-carboxylate | 5.66±1.72 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| propyl gallate | 42.29±3.93 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| propylparaben | 38.60±1.67 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| proscillaridin | 0.09±0.02 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| pyraclostrobin | 6.35±1.92 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| pyridate | 33.08±4.58 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| pyrinuron | 26.28±1.71 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| pyrvinium pamoate | 2.02±1.20 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| quercetin | 2.69±2.26 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| quercetin dihydrate | 6.20±2.32 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| rac benidipine hydrochloride | 14.96±3.18 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| rafoxanide | 3.27±1.76 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| raloxifene | 5.05±3.99 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| raloxifene hydrochloride | 6.69±1.65 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| resveratrol | 1.60±0.43 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Rhein | 6.06±5.91 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| riboflavin | 7.02±1.78 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| rifampicin | 25.06±6.38 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| rifapentine | 1.46±0.26 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| rimonabant | 25.60±1.67 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| rolicyclidine | 22.29±2.32 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Rotenone | 17.38±1.94 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| salicylanilide | 3.71±1.27 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| selenious acid | 15.97±22.77 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| siduron | 41.65±21.12 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| silwet l77 | 5.66±1.03 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| rapamycin | 20.08±2.07 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| sodium (4-fluoro-2-{[(1s)-1-phenylpropyl]carbamoyl}phenyl)(quinolin-8-ylsulfonyl)azanide | 4.42±6.97 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| sodium 2-phenylphenate tetrahydrate | 18.53±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| sodium bithionolate | 0.91±0.78 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| sodium warfarin | 38.57±12.82 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| sofalcone | 24.64±1.67 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| sorafenib | 0.96±0.09 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| sp600125 | 0.92±0.14 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| spiclomazine hydrochloride | 34.80±2.36 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| spiperone | 3.62±0.24 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| su-5416 | 12.53±1.78 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| sulfanitran | 26.60±8.77 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| surinabant | 33.08±16.61 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| talniflumate | 27.00±2.56 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tamibarotene | 25.68±1.05 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tamsulosin hydrochloride | 27.20±2.92 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tau-fluvalinate | 37.16±15.12 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tenidap | 12.53±1.19 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tenonitrozole | 0.73±0.12 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tenovin-1 | 3.27±2.74 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tenoxicam | 8.36±1.07 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tert-butyl 4-hydroxybenzoate | 25.29±7.32 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tetra-aminopyrimidine sulfate | 18.70±11.39 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tetrabromophenolphthalein ethyl ester | 23.80±6.89 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tetrabutyltin | 5.66±1.03 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tetradecylpyridinium bromide | 22.54±4.10 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tetradifon | 15.34±7.43 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tetraiodoethene | 5.45±1.27 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tetra-n-octylammonium bromide | 0.13±0.09 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tetraoctylphosphonium bromide | 0.18±0.12 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tetrasul | 1.77±0.25 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| thidiazuron | 3.43±0.73 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| thiram | 1.94±25.92 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tibrofan | 0.79±0.11 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tioxidazole | 7.50±1.75 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Tipranavir | 26.60±4.94 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tolclofos-methyl | 30.64±5.80 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Tolfenamic Acid | 11.88±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| toluidine blue | 3.48±1.60 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tolvaptan | 17.44±8.01 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| transfluthrin | 25.01±4.09 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tribenoside | 11.80±0.80 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tribromosalan | 1.12±0.00 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tributyltetradecylphosphonium chloride | 0.71±0.15 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tributyltin benzoate | 0.15±0.23 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tributyltin chloride | 0.11±0.02 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tributyltin methacrylate | 0.07±0.01 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tricirbine | 1.21±1.51 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| triclabendazole | 1.84±0.15 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| triclocarban | 0.14±0.05 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| triclosan | 1.50±0.88 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| triethoxy(2-methylpropyl)silane | 28.92±6.98 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| triethyltin bromide | 0.02±0.02 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| trifluralin | 46.68±9.14 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| trihexyltetradecylphosphonium bromide | 0.84±0.24 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| trihexyltetradecylphosphonium chloride | 0.77±0.35 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| trihexyltetradecylphosphonium dicyanamide | 0.39±0.19 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| trihexyltetradecylphosphonium hexafluorophosphate | 0.43±0.17 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| triphenyl phosphate | 1.38±1.48 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| triphenylethylene | 35.72±14.82 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| triphenyltin acetate | 0.12±0.04 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| triphenyltin fluoride | 0.47±0.31 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| triphenyltin hydroxide | 0.12±0.03 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tris(2,3-dibromopropyl) phosphate | 45.81±8.72 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Tyrothricin | 0.24±0.05 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| tyrphostin 23 | 17.70±6.46 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| vatalanib | 25.60±4.41 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Verteporfin | 3.27±1.85 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| zafirlukast | 10.59±1.22 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| zearalenone | 4.67±1.77 | human | qHTS-HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| (1,1,3,3-tetramethylbutyl)phenol | 3.98 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| (1'-ethyl-6,7-dihydro-5h-spiro[furo[2,3-f]indole-3,4'-piperidin]-5-yl)[2'-methyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-yl]methanone hydrochloride | 19.95 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| (2-ethyl-4-{[(4-{[4-(4-methoxyphenyl)piperazin-1-yl]methyl}-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]sulfanyl}phenoxy)acetic acid | 31.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| (5-chloro-2-hydroxyphenyl)phenylmethanone | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| (5s,8s)-5-(3,4-dichlorophenyl)-8-(methylamino)-5,6,7,8-tetrahydronaphthalene-2-sulfonamide | 10 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| (acryloyloxy)(tributyl)stannane | 0.4 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| (n-6)-methyladenine | 6.31 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Diethylstilbestrol | 5.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-(2,3,8,8-tetramethyl-1,2,3,4,5,6,7,8-octahydronaphthalen-2-yl)ethanone | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-(3,5,5,6,8,8-hexamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethanone | 28.18 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,1,1-trichloropropanone | 3.16 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,1,2-trimethyl-1h-benzo[e]indole | 10 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,1':3',1''-terphenyl | 50.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,2,5,6,9,10-hexabromocyclododecane | 6.31 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,2-benzisothiazolin-3-one | 17.78 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,2-phenylenediamine | 2.51 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,2-phenylenediamine dihydrochloride | 1.78 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,3,5-tris(4-tert-butyl-3-hydroxy-2,6-dimethylbenzyl)-1,3,5-triazinane-2,4,6-trione | 44.67 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,3-didecyl-2-methylimidazolium chloride | 3.16 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,3-diiminobenz(f)isoindoline | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,3-diphenyl-1,3-propanedione | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,4-benzenediamine | 2.18 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,4-diaminoanthraquinone | 0.22 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,4-dihydroxyanthracene-9,10-dione | 8.91 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,4-naphthalenediamine | 2 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,5-naphthalenediamine | 3.16 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1,8-dihydroxy-4,5-dinitroanthraquinone | 0.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Mito-4509 | 22.39 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 17alpha-ethinylestradiol | 15.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-amino-2-methylanthraquinone | 2.51 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-benzyl-1-{[3-(4-chlorophenyl)-5-methyl-1-benzofuran-2-yl]methyl}-3-(2,4,6-trifluorophenyl)urea | 56.23 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-decyl-3-methylimidazolium tetrafluoroborate | 7.08 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-decyl-3-methylimidazolium trifluoromethanesulfonate | 7.08 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-dodecyl-3-methylimidazolium hexafluorophosphate | 5.01 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-fluoro-2,4-dinitrobenzene | 5.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1h,3h-naphtho(1,8-cd)pyran-1,3-dione | 7.94 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1h-benzo[de]isoquinoline-1,3(2h)-dione | 14.13 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1h-indole-2-carboxamide, n-[(3r)-1-(2-fluorophenyl)-3,4,6,7-tetrahydro-4-oxopyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- | 13.77 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-hydroxypyrene | 7.08 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-isocyanato-3-(trifluoromethyl)benzene | 6.31 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-methyl-3-octylimidazolium hexafluorophosphate | 25.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-methyl-3-octylimidazolium tetrafluoroborate | 19.95 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-methyl-3-octylimidazolium trifluoromethanesulfonate | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-methylpyrene | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-naphthol | 31.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-nitropyrene | 6.31 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Edaravone | 28.18 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 1-trans-delta-9-tetrahydrocannabinol | 15.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-(4-hydroxybenzyl)phenol | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-(butan-2-yl)phenol | 25.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-(thiocyanomethylthio)benzothiazole | 56.23 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2',4,4',5-pentabromodiphenyl ether | 4.47 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2',6,6'-tetrachlorobisphenol a | 6.31 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2'4,4'-tetrabromodiphenyl ether | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane | 10 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2-bis[(benzoyloxy)methyl]dibenzoate propanediol | 7.08 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2'-dichlorobiphenyl | 63.1 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2'-dihydroxy-4,4'-dimethoxybenzophenone | 12.59 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2'-dihydroxy-4-methoxybenzophenone | 5.24 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2'-methylenebis(4-methyl-6-tert-butylphenol) | 2 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2'-methylenebis(ethyl-6-tert-butylphenol) | 2 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,3',4,4'-tetrahydroxybenzophenone | 8.91 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,3,4,5-tetrachlorophenol | 7.94 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,3,4-trichlorophenol | 7.94 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,3,5,6-tetrachlorophenol | 8.91 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,3,5-trichlorophenol | 6.31 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4,5-trichlorophenol sodium salt | 10 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4,6-trinitro-1,3-dimethyl-5-tert-butylbenzene | 7.94 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4-bis(1-methyl-1-phenylethyl)phenol | 2.82 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4-diaminoanisole sulfate | 7.94 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4-dichloro-3,5-dimethylphenol | 8.91 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4-diisopropylphenol | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,4-di-tert-butylphenol | 3.98 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,5-bis(2-methylbutan-2-yl)benzene-1,4-diol | 3.55 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,5-di-tert-butylbenzene-1,4-diol | 7.94 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,6-bis-(1,1-dimethylethyl)-2,5-cyclohexadiene-1,4-dione | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,6-di(butan-2-yl)phenol | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,6-diaminopyridine | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,6-di-tert-butyl-4-nitrophenol | 0.11 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,6-toluenediamine | 28.18 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 24r,25-dihydroxyvitamin d3 | 15.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-Acetylaminofluorene | 31.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-amino-4-(p-nitrophenyl)thiazole | 8.91 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-amino-4,6-dinitrophenol | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-amino-4-chloro-5-nitrophenol | 25.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-amino-4-chlorobenzothiazole | 31.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-amino-5-nitrophenol | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-amino-6-nitrobenzothiazole | 44.67 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-aminoanthracene | 3.55 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-aminoanthraquinone | 1.26 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-chloro-4-phenylphenol | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-dodecylisoquinolinium tosylate | 4.35 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-ethylphenol | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-hydrazino-4-(4-aminophenyl) thiazole | 0.4 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-hydrazino-4-(4-nitrophenyl)thiazole | 1.26 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-hydrazino-4-phenylthiazole | 10 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-hydroxyanthraquinone | 7.08 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-isovaleryl-1,3-indanedione | 56.23 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-methyl-1-nitroanthraquinone | 2.77 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-methylanthraquinone | 11.22 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-naphthalenesulfonic acid, 7-amino-4-hydroxy- | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-naphthalenol | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-nitro-1,4-phenylenediamine | 12.59 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-nitrofluorene | 50.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-phenylphenol | 28.18 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-propenal,3,3-diphenyl- | 56.23 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-tert-butyl-4-ethylphenol | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-tert-butyl-4-methoxyphenol | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2-tert-butyl-5-methylphenol | 5.01 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-(5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexanol | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,3',4,4'-tetraaminobiphenyl tetrahydrochloride | 2 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,3',5,5'-tetraiodothyroacetic acid | 39.04 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,3'-diaminobenzidine | 4.47 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,3'-dimethylbisphenol a | 11.22 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,3φ,5,5φ-tetrabromobisphenol a | 17.78 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,4,5-trichlorophenol | 5.01 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,4-dichlorophenol | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,5-dichlorophenol | 11.22 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3,5-dichlorosalicyl-3,4-dichloroanilide | 0.11 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-acetylphenanthrene | 56.23 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-amino-9-ethylcarbazole hydrochloride | 14.13 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-hydroxybenzophenone | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-hydroxy-n-(3-nitrophenyl)naphthalene-2-carboxamide | 0.28 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-hydroxy-n-phenylaniline | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-methylbenzene-1,2-diamine | 28.18 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-methylcholanthrene | 25.19 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 3-methyl-n-phenylaniline | 28.18 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-(1,1,3,3-tetramethylbutyl)phenol | 4.89 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-(2-methylbutan-2-yl)phenol | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-(3-phenylpropyl)pyridine | 14.13 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-(benzyloxyl)phenol | 7.4 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-(butan-2-yl)phenol | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4,4-trifluoro-1-phenyl-1,3-butanedione | 31.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-diaminoazobenzene | 5.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-diaminobenzanilide | 7.08 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-dichlorodiphenyl sulfone | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-dinitrodiphenylurea | 0.97 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-methylenebis(2-chloroaniline) | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-sulfonylbis[2-(prop-2-en-1-yl)phenol] | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-thiobis(6-tert-butyl-m-cresol) | 3.16 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,4'-thiodiphenol | 25.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,6-dichloro-1,3-benzenediol | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4,6-di-tert-butyl-m-cresol | 2.51 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-amino-2,6-dichlorophenol | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-amino-2-nitrophenol | 14.13 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-amino-4φ-hydroxy-3-methyldiphenylamine | 14.13 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-benzylphenol | 31.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-chloro-1,2-diaminobenzene | 2 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-chloro-2-cyclopentylphenol | 6.31 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-chloro-3,5-dimethylphenol | 25.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-chlorophenyl isocyanate | 0.71 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-cumylphenol | 3.55 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4'-demethylepipodophyllotoxin | 2.18 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-dodecylphenol | 5.01 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-hexyl-4'-cyanobiphenyl | 31.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-hydroxybenzophenone | 28.18 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-methyl-2,6-dinitrophenol | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-nitroanthranilic acid | 17.78 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-nitro-n-phenylaniline | 8.91 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-nitrosophenol | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-octylphenol | 14.13 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-phenoxyphenol | 47.57 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-tert-butylcatechol | 31.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 4-tert-butylphenyl salicylate | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 5,7-dichloro-8-hydroxy-2-methylquinoline | 1.38 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 5alpha-dihydrotestosterone | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 5hpp-33 | 2.24 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Busulfan | 2 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 5-nitroacenaphthene | 56.23 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 6-hydroxy-2-naphthyl disulfide | 28.18 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 9-aminoacridine, monohydrochloride, monohydrate | 21.82 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 9-anthracenemethanol | 19.95 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 9-nitroanthracene | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 9-phenanthrol | 3.55 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| acenocoumarol | 9.32 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| aclarubicin hydrochloride | 2.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| acriflavine hydrochloride | 0.44 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Albendazole | 19.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| aldrin | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| alizarin | 13.77 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| allylestrenol | 31.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| aloe-emodin | 7.08 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| alpha-amylcinnamyl alcohol | 56.23 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ambazone | 3.98 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ami-193 | 7.74 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| aminoquinuride dihydrochloride | 27.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| amorolfine | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| amsacrine hydrochloride | 56.23 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| amylmetacresol | 8.69 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| apigenin | 3.55 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| aroclor 1260 | 12.59 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| arotinolol hydrochloride | 27.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| axitinib | 1.09 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| barban | 25.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bardoxolone methyl | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| barium chloride | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| basic blue 7 | 0.05 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bazedoxifene | 15.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| beclazone | 21.82 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benzbromarone | 13.77 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benzidine | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benzidine dihydrochloride | 17.65 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benziodarone | 4.35 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benzoic acid, 2-[(4-chloro-3-methylphenyl)amino]- | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benzyldimethyltetradecylammonium chloride dihydrate | 13.77 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benzyldodecyldimethylammonium bromide | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| benzylhydrazine dihydrochloride | 19.95 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| berberine chloride | 3.46 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| betamethasone dipropionate | 19.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bexarotene | 8.69 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bis(tributyltin)oxide | 0.31 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bisacodyl | 7.74 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Bisphenol A | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bisphenol a glycidyl methacrylate | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bisphenol af | 5.01 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bisphenol b | 10 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bisphenol e | 25.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bisphenol z | 19.95 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bithionol | 0.97 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bosutinib | 1.23 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bromadiolone | 4.35 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bromociclen | 15.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bromocriptine | 21.82 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bromocriptine mesylate | 13.5 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bromofenoxim | 3.98 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bromofos | 8.91 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bromoxynil octanoate | 31.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| broquinaldol | 12.59 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| bryostatin 1 | 0.001 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| butylparaben | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| c.i. 1040 | 7.74 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| c.i. basic orange 2 | 19.95 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| c.i. basic red 9 monohydrochloride | 0.56 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| c.i. basic violet 14 | 0.87 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| c.i. disperse blue 27 | 25.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| c.i. solvent yellow 14 | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| calcifediol | 12.27 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| calcipotriene | 21.82 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| calcitriol | 15.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| candesartan cilexetil | 11.22 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cannabinol | 1.09 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cantharidin | 0.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| CCCP | 0.25 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| carminomycin | 21.82 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chlorfenapyr | 0.04 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chlorfenethol | 12.59 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chlorfenson | 44.67 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chlorfluazuron | 12.59 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chlorophacinone | 3.55 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chloropropylate | 44.67 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chloroxine | 9.75 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chromomycin | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chrysarobin | 30.83 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| chrysin | 7.08 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ciclesonide | 15.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Ciglitazone | 14.13 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cilnidipine | 12.27 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cinalukast | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| clobetasol | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cloflucarban | 0.44 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| clofoctol | 4.35 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| clonixin | 22.39 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cloxyquin | 15.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| coumatetralyl | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| cresyl diphenyl phosphate | 3.55 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| curcumin | 2.51 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| d&c yellow 11 | 0.44 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| danthron | 15.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dantrolene sodium | 3.46 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| darbufelone mesylate | 5.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| deltamethrin | 50.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| deslanoside | 0.44 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| desogestrel | 27.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| devazepide | 10.94 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dexamethasone valerate | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diacerein | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dianiline | 21.82 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dibutyltin dilaurate | 27.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dichlofluanid | 25.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dichlorodiphenylsilane | 22.39 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diclazuril | 8.69 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dicofol | 8.91 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| N,N'-dicyclohexylcarbodiimide | 0.02 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dienestrol | 8.3 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Diethylstilbestrol | 6.31 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diethylstilbestrol dipropionate | 7.08 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| digitoxin | 0.06 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| digoxin | 0.13 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dinex | 0.71 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diniconazole | 8.91 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dinobuton | 7.94 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dinocap | 0.63 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dinoterb | 2.24 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diphenan | 19.95 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diphenoxylate hydrochloride | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diphenylcyclopropenone | 27.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| diphenylurea | 2.51 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| disperse red 82 | 6.31 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dithiazanine chloride | 0.15 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dithiazanine iodide | 0.03 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dodecyl gallate | 7.94 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dodecylparaben | 7.94 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| dodecylphenol | 3.16 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| doramapimod;bibr-796? | 21.82 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| doramectin | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ebselen | 19.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| emodin | 2.51 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| endosulfan sulfate | 17.78 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| endrin | 21.82 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| enterolactone | 10.72 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| eprinomectin (b1a, b1b mixture) | 8.69 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| equilin | 31.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| estradiol acetate | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ethacridine lactate hydrate | 5.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ethalfluralin | 44.67 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ethanol, 2,2'-((1-methylethylidene)bis((2,6-dibromo-4,1-phenylene)oxy))bis- | 10.97 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ethoxazene | 2.82 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ethynodiol diacetate | 21.82 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| etocarlide | 25.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| everolimus | 27.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ezetimibe | 8.69 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| famoxadone | 4.47 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fenamidone | 19.95 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fenarimol | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fenchlorphos | 6.15 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fendiline hydrochloride | 9.75 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fenhexamid | 17.78 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fenretinide | 4.89 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fentiazac | 19.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fenticlor | 5.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fenvalerate | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| flopropione | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fluazuron | 12.27 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| flubendiamide | 25.33 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| flucythrinate | 31.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Flufenamic Acid | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| flunixin meglumine | 7.4 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fluorodifen | 28.18 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fluorosalan | 0.19 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fluoxastrobin | 11.22 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| folpet | 14.13 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| forchlorfenuron | 1 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| formononetin | 17.78 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| fulvestrant | 5.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| geliomycin | 0.19 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| genistein | 10 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| gentian violet | 0.35 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| gramicidin | 0.04 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| halobetasol propionate | 13.77 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| heptachlor | 31.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Hexachlorophene | 0.63 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| indole-3-pyruvic acid | 11.22 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| indoxacarb | 15.27 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| iodophthalein | 4.35 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| iodophthalein sodium | 6.9 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| isobutylparaben | 14.13 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| isodrin | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| isoxaben | 14.13 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| isoxicam | 2.75 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| israpafant | 27.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| kaempferol | 6.76 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| kepone | 2.82 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Ketoconazole | 5.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lambda-cyhalothrin | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lanatoside a | 0.14 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lanatoside b | 0.69 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lanatoside c | 0.31 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lapachol | 31.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lasalocid sodium | 1.38 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lercanidipine hydrochloride | 8.69 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lestaurtinib | 5.62 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lornoxicam | 6.15 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lufenuron | 14.13 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lynestrenol | 7.4 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| lysergide | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| malachite green oxalate | 27.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| malotilate | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| manidipine | 27.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Mebendazole | 2.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| mepartricin | 6.9 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| mepronil | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| mesotrione | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| metanixin | 21.82 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methfuroxam | 17.78 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methisazone | 12.59 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Methoxychlor | 28.18 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methyl 2,4-dihydroxy-3,6-dimethylbenzoate | 25.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methyl triclosan | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methyl violet | 0.44 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methyldigoxin | 0.24 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Methylene Blue | 2.75 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methylene blue trihydrate | 4.82 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| methyltrioctylammonium trifluoromethanesulfonate | 2.24 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| metochalcone | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| mgk-264 | 28.18 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| miripirium chloride | 8.69 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| mk-2206 | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| mometasone furoate | 8.3 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| n,n-diethylbenzene-1,4-diamine | 7.94 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| n,n-dimethyl-p-phenylenediamine | 7.08 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| n-benzyl-6-ethoxy-4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxamide | 15.85 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| nelfinavir mesylate | 30.83 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Niclosamide | 0.1 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| niflumic acid | 15.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| nifuroxazide | 2.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Nimesulide | 4.16 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ninhydrin | 56.23 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Nitazoxanide | 1.26 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Nitrofurantoin | 8.69 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| nitrovin | 5.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| nitroxoline | 19.95 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| n-methyl-n,n-dioctyloctan-1-aminium chloride | 10 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| nocodazole | 2.18 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| nonylparaben | 7.94 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| norelgestromin | 19.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| noristerat | 21.82 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| n-phenyl-1,4-benzenediamine hydrochloride | 28.18 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| o,p'-ddd | 19.45 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| o,p'-ddt | 25.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| osalmid | 6.31 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| ouabain | 0.22 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| oxyphenisatin acetate | 17.34 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| p,p'-ddd | 39.81 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| p,p'-dde | 44.67 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| p,p'-ddt | 30.83 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| palmatine chloride hydrate | 12.59 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| p-benzoquinone dioxime | 25.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| penfluridol | 27.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| 2,2',4,4',5-pentabromodiphenyl ether | 8.91 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| pentabromophenol | 7.94 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Pentachlorophenol | 8.9 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| pentylparaben | 14.13 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| perfluorooctanesulfonamide | 2.51 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| phenmedipham | 7.08 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| phenol, 4,4'-butylidenebis[2-(1,1-dimethylethyl)-5-methyl- | 7.08 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| phenol, 4-methyl-, reaction products with dicyclopentadiene and isobutylene | 8.69 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| phenolphthalein | 25.12 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| phenoxybenzamine hydrochloride | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| phenyl isothiocyanate | 35.48 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| phloretin | 11.22 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| picoxystrobin | 1 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| picropodophyllin | 0.05 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| pinacyanol | 0.02 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| pirarubicin | 0.69 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| Piroxicam | 5.88 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| polyethylene glycol (9z)-9-octadecenyl ether | 7.94 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| polyoxyethylene(10)nonylphenyl ether | 4.89 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| p-phenylazophenol | 10 | human | HepG2 | MMP assay | decrease | Positive | IC50 | 163 | |
| prodiamine | 8.91 | human | HepG2 | MMP assay | decrease |